Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.

Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I.Arthritis Rheum. 2005 Nov;52(11):3360-70. doi: 10.1002/art.21298.PMID: 16255010 Clinical Trial.